{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:52:11Z","timestamp":1764251531055,"version":"3.41.2"},"reference-count":15,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Data remain limited on the most appropriate valganciclovir (<jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content>) dosing strategy for cytomegalovirus (<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>) prophylaxis and treatment in pediatric organ transplant recipients. Therefore, the objective of this study was to describe methods used to calculate <jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content> dosing among pediatric transplant centers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A survey of pharmacists was conducted to assess <jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content> dosing strategies for <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> prophylaxis and treatment among pediatric organ transplant centers in the U.S.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Of 54 centers that perform pediatric organ transplants, 22 (40.7%) centers responded to the survey. Fourteen centers (53.8%) utilize the Food and Drug Administration (<jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content>) recommended <jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content> dosing strategy of 7\u00a0\u00d7\u00a0body surface area (<jats:styled-content style=\"fixed-case\">BSA<\/jats:styled-content>)\u00a0\u00d7\u00a0creatinine clearance (CrCl) for <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> prophylaxis. Other dosing strategies reported included weight based and 520\u00a0mg\/m<jats:sup>2<\/jats:sup>\u00a0\u00d7\u00a0<jats:styled-content style=\"fixed-case\">BSA<\/jats:styled-content> per day. Dosing strategies of <jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content> for the treatment of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> also differed across centers, with a majority (43.5%) using 7\u00a0\u00d7\u00a0<jats:styled-content style=\"fixed-case\">BSA<\/jats:styled-content>\u00a0\u00d7\u00a0CrCl twice daily.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Less than two\u2010thirds of centers utilize the <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content>\u2010approved daily dosing regimen with various methods of CrCl calculation and serum creatinine assay measurements used. More retrospective and prospective studies with clinical outcomes associated with <jats:styled-content style=\"fixed-case\">VCGV<\/jats:styled-content> dosing strategies are warranted to determine the most appropriate prophylaxis and treatment strategies for <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ctr.13369","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T06:37:29Z","timestamp":1533623849000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients"],"prefix":"10.1111","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2438-0349","authenticated-orcid":false,"given":"Suhail","family":"Shaikh","sequence":"first","affiliation":[{"name":"Department of Pharmacy MedStar Georgetown University Hospital  Washington District of Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Jasiak\u2010Panek","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Ann &amp; Robert H. Lurie Children's Hospital of Chicago  Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong M.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy College of Pharmacy, University of Michigan  Ann Arbor Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"volume-title":"Valcyte\u00ae [package insert]","year":"2017","key":"e_1_2_7_2_1"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2009.00478.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182463a19"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12030"},{"key":"e_1_2_7_6_1","unstructured":"FDA Drug Safety Communication: New dosing recommendations to prevent potential Valcyte (valganciclovir) overdose in pediatric transplant patients. 2010.https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm225727.htm. Accessed May 25 2018."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02528.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.01910.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544050-00003"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001595"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12397"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12349"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12343"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2006.00669.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(02)70054-1"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12179"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fctr.13369","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.13369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T07:32:46Z","timestamp":1694331166000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.13369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/ctr.13369"],"URL":"https:\/\/doi.org\/10.1111\/ctr.13369","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"type":"print","value":"0902-0063"},{"type":"electronic","value":"1399-0012"}],"subject":[],"published":{"date-parts":[[2018,8,20]]},"assertion":[{"value":"2018-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13369"}}